TTA-AGE: P3 Therapeutics applies to the EIC Pathfinder Challenges
P3 Therapeutics has submitted the TTA-AGE proposal to the EIC Pathfinder Challenges 2026. Like our EUROSTARS 4 application, it fits the organ-on-chip, NAM-based approach behind our biomarker-driven development.
On 28 October 2026 P3 Therapeutics submitted the TTA-AGE proposal to the European Innovation Council’s Pathfinder Challenges 2026 (HORIZON-EIC-2026-PATHFINDERCHALLENGES-01), with the support of GrantLab.
The application fits the organ-on-chip approach and the new approach methodology (NAM) line described on the Science page — the same direction as our pending EUROSTARS 4 application, 12259-GATEWAY.
Both applications are pending. Evaluation results for the Pathfinder call are usually announced within five months of the call deadline; we will share the outcome here.